Related Experiment Video
Updated: Sep 1, 2025

07:02
Monitoring Neuronal Survival via Longitudinal Fluorescence Microscopy
Published on: January 19, 2019
6.6K
TREMble Before TREM2: The Mighty Microglial Receptor Conferring Neuroprotective Properties in TDP-43 Mediated
William A Mills1,2,3, Ukpong B Eyo4,5,6
1Brain Immunology and Glia Center, University of Virginia, Charlottesville, VA, 22903, USA. gne7xr@virginia.edu.
Neuroscience Bulletin
|August 17, 2022
Abstract
No abstract available in PubMed .
Related Concept Videos
Enzyme-linked Receptors
79.6K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
79.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
423
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
423
Alzheimer's Disease: Treatment
251
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
251

